ERBB2 and breast cancer: Testing the breast cancer cell line T47D, which has low levels of HER2 (4.00 × 104 rec/cell) and even lower levels of PRLR (2.73 × 104 rec/cell) expression, an anti-HER2 ADC (DM1 payload) was completely non-effective.